HIV drug interactions: The good, the bad, and the other

被引:21
作者
Rainey, PM [1 ]
机构
[1] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
关键词
antiretroviral; HIV; drug interaction; injection drug use; therapeutic drug monitoring;
D O I
10.1097/00007691-200202000-00005
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Highly active antiretroviral therapy, involving treatment with three or four antiretroviral agents, has greatly improved the effectiveness of therapy for human immunodeficiency virus (HIV) infection. It has also extended the number of possible drug interactions that may occur in treated patients. There are 105 possible two-drug interactions among the 15 currently approved antiretroviral agents. Well-characterized interactions involving inhibition of drug metabolism have been exploited to reduce dose size or frequency and to simplify treatment regimens. Many additional interactions are possible with other drugs used to treat or prevent complications of HIV infection. Interactions with methadone and other opiate abuse therapies are also of concern. The usefulness of therapeutic drug monitoring for antiretroviral drugs remains controversial. However, drug measurements before introduction of an interacting drug can establish patient-specific targets that can guide subsequent dosing adjustment.
引用
收藏
页码:26 / 31
页数:6
相关论文
共 28 条
[1]   Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone [J].
Altice, FL ;
Friedland, GH ;
Cooney, EL .
AIDS, 1999, 13 (08) :957-962
[2]   The role of therapeutic drug monitoring in treatment of HIV infection [J].
Back, DJ ;
Khoo, SH ;
Gibbons, SE ;
Merry, C .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (04) :301-308
[3]  
Beauverie P, 1998, AIDS, V12, P2510
[4]   Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel [J].
Carpenter, CCJ ;
Cooper, DA ;
Fischl, MA ;
Gatell, JM ;
Gazzard, BG ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schechter, M ;
Schooley, RT ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (03) :381-390
[5]  
*CDCP, 2001, AIDS CAS EXP CAT
[6]  
Chesney MA, 1999, AIDS, V13, pS271
[7]   Antiretroviral therapy for drug users [J].
Clarke, SM ;
Mulcahy, FM .
INTERNATIONAL JOURNAL OF STD & AIDS, 2000, 11 (10) :627-631
[8]   The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz [J].
Clarke, SM ;
Mulcahy, FM ;
Tjia, J ;
Reynolds, HE ;
Gibbons, SE ;
Barry, MG ;
Back, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (03) :213-217
[9]   Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits [J].
Flexner, C .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2000, 40 :649-674
[10]  
FRIEDLAND G, 1999, MED MANAGEMENT AIDS